Advanced Proteome Therapeutics (CVE:APC) on Tuesday announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's claims over its Foundation Trinity cancer fighting technology.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent has a projected expiration date that would be no earlier than October 2029.
The drug developer's potentially groundbreaking cancer therapy features a three-in-one treatment that acts as a targeted, combination and homogeneous therapy - all in a single agent.
The technology is based on a proprietary platform that can be used to attach known therapeutics to specific sites on proteins - in this case, proteins that have shown affinity for specific cancer cells, hence the targeted and combination therapy.
The attachments are designed to boost the properties of the protein targeted for the specific cancer cells, giving it additional therapeutic abilities.
The patent allowance announced today specifically covers Advanced Proteome's claims over the composition of matter that protects the modified forms of proteins it has prepared, which are being used as delivery systems to specific cancer cells.
The modified proteins enable the formation of homogeneous protein conjugates that are being targeted for various cancer cells.“We are very pleased to announce this Notice of Allowance that is a key to our ability to employ combination therapy in a homogenous manner in a single agent,” said president and CEO Alexander Krantz, Ph.D.
“It is one of a number of pending patent applications with the USPTO expected to cover aspects of our Foundation Trinity technology, which will employ targeted therapy, combination therapy, and homogenous therapy versus cancer cells.”
The company said it is also pursuing patent applications related to its Foundation Trinity technology in multiple jurisdictions outside the U.S.
Late last month, Advanced Proteome told Proactive Investors that the homogeneity aspect of its therapy originates from the use of a protein not only as a delivery system, but also as a scaffold on which to attach each anti-cancer entity to its own specific site on the protein - key to efficient manufacturing and product development.
The feature allows the company to produce single agents, or protein conjugates, bearing multiple therapies.
The company said then that it was already seeking contracts with laboratories to test its technology, and once this is complete, it will begin a first round of testing, with the single agents to be screened for their ability to target cancer cells specifically, and for any obvious toxic effects on healthy cells.
Over the next six months, Advanced Proteome said it also expects that any promising agents will undergo animal testing in a second round, to determine the potency and toxicity of the therapy.
The drug developer recently raised $855,000 in private placement financings and is expecting that as it delivers on its goals, it will raise more funds, with its stock set to appreciate in value.